Literature DB >> 8270885

Distinct types of lung disease caused by functional subsets of antiviral T cells.

W H Alwan1, W J Kozlowska, P J Openshaw.   

Abstract

T cells appear to play a central role in viral bronchiolitis, but the effects of different functional and phenotypic subgroups of T cells have not been defined. To test the activities of T cells recognizing individual proteins of respiratory syncytial (RS) virus, virus-specific T cell lines were produced from mice primed by scarification with recombinant vaccinia viruses expressing the major surface glycoprotein (G), fusion protein (F) or second matrix (22K) protein of RS virus. As previously reported, the in vitro characteristics of these cells are predetermined by the choice of RS virus protein: 22K-specific cells are predominantly class I-restricted cytolytic CD8+ cells; F-specific cells, a mixture of cytolytic CD8+ cells and CD4+ cells with a T helper 1 cell (Th1) cytokine secretion profile, whereas those from G-sensitized mice are almost exclusively CD4+, with Th2 characteristics. Mice infected intranasally with RS virus showed mild illness and recovered fully, but developed respiratory distress after intravenous injections of T cells. Dose-for-dose, infected mice receiving G-specific cells suffered the most severe (sometimes fatal) illness, characterized by lung hemorrhage, pulmonary neutrophil recruitment (shock lung) and intense pulmonary eosinophilia. This disease was further enhanced by coinjection of 22K-specific cells, which alone caused mild shock lung without eosinophilia. F-specific cells caused minimal enhancement of pathology and had little or no effect on the disease caused by G-specific cells. Each cell line reduced lung virus titer and combined injections of G- and 22K-specific cells eliminated infection completely. The in vitro characteristics of these antiviral T cell lines therefore predict the pathological effects in vivo. Moreover, different forms of viral bronchiolitis can be caused by functionally distinct types of activated T cell.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8270885      PMCID: PMC2191312          DOI: 10.1084/jem.179.1.81

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  41 in total

1.  Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.

Authors:  P J Openshaw; S L Clarke; F M Record
Journal:  Int Immunol       Date:  1992-04       Impact factor: 4.823

2.  Childhood respiratory infection and adult chronic bronchitis in England and Wales.

Authors:  D J Barker; C Osmond
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

3.  Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.

Authors:  E J Stott; L A Ball; K K Young; J Furze; G W Wertz
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

Review 4.  Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus.

Authors:  K McIntosh; J M Fishaut
Journal:  Prog Med Virol       Date:  1980

5.  Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins.

Authors:  W H Alwan; P J Openshaw
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

6.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.

Authors:  M Connors; A B Kulkarni; C Y Firestone; K L Holmes; H C Morse; A V Sotnikov; B R Murphy
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors.

Authors:  L A Ball; K K Young; K Anderson; P L Collins; G W Wertz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

8.  Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins.

Authors:  W H Alwan; F M Record; P J Openshaw
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

9.  Childhood asthma following hospitalization with acute viral bronchiolitis in infancy.

Authors:  P D Sly; M E Hibbert
Journal:  Pediatr Pulmonol       Date:  1989

10.  The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children.

Authors:  K McIntosh; E F Ellis; L S Hoffman; T G Lybass; J J Eller; V A Fulginiti
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

View more
  116 in total

1.  A defective type 1 response to rhinovirus in atopic asthma.

Authors:  N G Papadopoulos; L A Stanciu; A Papi; S T Holgate; S L Johnston
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

2.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

3.  Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

Authors:  K Bendelja; A Gagro; A Bace; R Lokar-Kolbas; V Krsulovic-Hresic; V Drazenovic; G Mlinaric-Galinovic; S Rabatic
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein.

Authors:  A H Brandenburg; L de Waal; H H Timmerman; P Hoogerhout; R L de Swart; A D Osterhaus
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Immunological responses to respiratory syncytial virus infection in infancy.

Authors:  R L Smyth; J N Fletcher; H M Thomas; C A Hart
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

6.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.

Authors:  Whitney W Stevens; Taeg S Kim; Lindsey M Pujanauski; Xueli Hao; Thomas J Braciale
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

9.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves.

Authors:  G Taylor; L H Thomas; S G Wyld; J Furze; P Sopp; C J Howard
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.